Regeneron Pharmaceuticals ROE - Return on Equity 2010-2025 | REGN
- Regeneron Pharmaceuticals average return on equity for 2024 was 15.95, a 9.63% decline from 2023.
- Regeneron Pharmaceuticals average return on equity for 2023 was 17.65, a 41.86% decline from 2022.
- Regeneron Pharmaceuticals average return on equity for 2022 was 30.36, a 36.45% decline from 2021.
Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.